Paclitaxcel Q3W for adenocarcinoma, mucinous

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Aug 2026: Trial started, NCT07795749
  2. 31 Aug 2026: Trial registered, NCT07795749

The trials

NCT07795749: Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)

State
Under way
Phase
Phase 2
People
55 planned
Started
4 Aug 2026
Primary completion
31 Aug 2029
Arms
CohtAQ3W: Cohort A Gastric/Esophageal Carcinoma (Paclitaxel Q3W), CohtBQ3W: Cohort B Colorectal/Appendiceal Adenocarcinoma (Paclitaxel Q3W), CohtCQ3W: Cohort C Other Malignancies of the Digestive Tract (Paclitaxel Q3W)
Results
None posted
  1. 4 Aug 2026: Trial started
  2. 31 Aug 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.